Roivant says Phase 2 PHocus trial shows mosliciguat cuts pulmonary vascular resistance 56.3% in PH-ILD

• Roivant reported positive Phase 2 results for inhaled mosliciguat in pulmonary hypertension tied to interstitial lung disease.
• Results are being presented today at the European Respiratory Society International Congress 2026.
• The trial showed meaningful improvement in lung blood-flow measures, walking capacity, and a cardiac stress biomarker versus placebo.
• Mosliciguat was well tolerated, with fewer cough reports than placebo, supporting differentiation from inhaled prostacyclin options.
• A Phase 3 trial in the same condition has started, moving the program into late-stage development with enrollment underway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080600PRIMZONEFULLFEED9822522) on September 08, 2026, and is solely responsible for the information contained therein.